venBio Global Strategic — 2021 Investments
6 investments dated 2021 · listed companies and verified rows first · show all
San Diego, US
Board seatYvonne Yamanaka· per SEC Form D · $120M raise · filed Apr 2021
Co-investors5AM VenturesRA Capital
HealthtechSeattle, US
John D. Hoekman(Executive Officer, Director)
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatAaron Royston· per SEC Form D · $1.9M raise · filed Apr 2021
Co-investors5AM VenturesB Capital GroupvenBio PartnersWestlake Village BioPartners
Developing transformative therapies to advance treatment of gastrointestinal disorders with significant unmet medical need.
Woburn, US
Board seatAaron Royston· per SEC Form D · filed Jul 2021
Co-investorsSamsara BioCapitalWestlake Village BioPartners
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Board seatAaron Royston· per SEC Form D · $112M raise · filed Sep 2021
Co-investorsBlackRockEndeavour VisionMVM Life Science PartnersRTW Investments L.P.Soleus CapitalVivo Capital
Tallac Therapeutics is a biopharmaceutical company developing oligonucleotide-based antibody drug conjugates (ADCs) to treat cancer, including its Toll-like Receptor Agonist Antibody Conjugates (TRAAC) that deliver a TLR9 agonist to activate immune responses within the tumor microenvironment.
BiotechHealthtechBurlingame, US
Board seatCorey Goodman· per SEC Form D · $61.6M raise · filed Jul 2021
Co-investorsLightstone VenturesMRL Ventures FundvenBio Partners
San Diego, US
Mark S. Forman(Executive Officer)Matthew Moore(Executive Officer)John Nuss(Executive Officer)Jigar Choksey(Director)Martin Auster(Executive Officer)Christopher W. Krueger(Executive Officer)
Board seatAaron RoystonRichard Gaster· per SEC Form D · $51M raise · filed Sep 2021
Co-investorsNew Science VenturesThird Point VenturesvenBio PartnersSilverArc Private
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.